Aon plc announced on August 18, 2025, a strategic investment in eMed Population Health, Inc., an emerging leader in the delivery of GLP-1 programs. This partnership aims to enhance employer-sponsored access to GLP-1 therapies and scale solutions for obesity. The investment follows the successful launch earlier this year of Aon's own subsidized GLP-1 weight management benefit program for its U.S. workforce, developed by eMed.
In the six months since Aon's program launched, over 1,200 people registered, with participants achieving an average weight loss of 22.4 pounds and a retention rate of 95 percent. Lisa Stevens, Chief Administrative Officer for Aon, highlighted the importance of including GLP-1 coverage in Aon's Total Rewards strategy, underscoring how employer decisions shape workforce health and performance. This investment enables Aon to play an active role in offering a differentiated global solution focused on medication adherence.
The collaboration marks a major milestone in eMed's mission to deliver effective and sustainable care through an integrated, data-driven experience. Farheen Dam, Head of Health for North America at Aon, noted that GLP-1s are not a one-size-fits-all strategy, emphasizing the need for data, modeling, and strategic guidance from Aon's clinical, actuarial, and pharmacy teams. This partnership aims to help employers reduce long-term health costs while improving quality of life for their people.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.